关注
Inna Dolzhikova
Inna Dolzhikova
ФГБУ "НИЦЭМ им. Н.Ф.Гамалеи" Минздрава России
在 gamaleya.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, ...
The Lancet 397 (10275), 671-681, 2021
20692021
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
DY Logunov, IV Dolzhikova, OV Zubkova, AI Tukhvatulin, ...
The Lancet 396 (10255), 887-897, 2020
12642020
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
IV Dolzhikova, OV Zubkova, AI Tukhvatulin, AS Dzharullaeva, ...
Human vaccines & immunotherapeutics 13 (3), 613-620, 2017
1362017
Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow endemic SARS …
VA Gushchin, IV Dolzhikova, AM Shchetinin, AS Odintsova, AE Siniavin, ...
Vaccines 9 (7), 779, 2021
1282021
SERS-based aptasensor for rapid quantitative detection of SARS-CoV-2
E Zavyalova, O Ambartsumyan, G Zhdanov, D Gribanyov, V Gushchin, ...
Nanomaterials 11 (6), 1394, 2021
682021
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in …
AI Tukhvatulin, IV Dolzhikova, DV Shcheblyakov, OV Zubkova, ...
The Lancet Regional Health–Europe 11, 2021
662021
Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses
AI Tukhvatulin, AS Dzharullaeva, NM Tukhvatulina, DV Shcheblyakov, ...
PLoS One 11 (5), e0155650, 2016
502016
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific T cells and antibodies in coronavirus disease 2019 (COVID-19) protection: a prospective study
IA Molodtsov, E Kegeles, AN Mitin, O Mityaeva, OE Musatova, AE Panova, ...
Clinical Infectious Diseases 75 (1), e1-e9, 2022
33*2022
Virus-vectored Ebola vaccines
IV Dolzhikova, EA Tokarskaya, AS Dzharullaeva, AI Tukhvatulin, ...
Acta Naturae (англоязычная версия) 9 (3 (33)), 4-11, 2017
322017
Safety and efficacy of the Russian COVID-19 vaccine: more information needed–Authors’ reply
DY Logunov, IV Dolzhikova, AI Tukhvatullin, DV Shcheblyakov
The Lancet 396 (10256), e54-e55, 2020
282020
Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals
D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, ...
Vaccines 10 (5), 817, 2022
272022
Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern
IA Favorskaya, DV Shcheblyakov, IB Esmagambetov, IV Dolzhikova, ...
Frontiers in immunology 13, 822159, 2022
232022
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B. 1.1. 529 (Omicron) SARS-CoV-2 variant
IV Dolzhikova, AA Iliukhina, AV Kovyrshina, AV Kuzina, VA Gushchin, ...
medRxiv, 2021.12. 17.21267976, 2021
232021
Impact of pathogen reduction methods on immunological properties of the COVID19 convalescent plasma
AI Kostin, MN Lundgren, AY Bulanov, EA Ladygina, KS Chirkova, ...
Vox Sanguinis 116 (6), 665-672, 2021
212021
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial–Authors' reply
DY Logunov, IV Dolzhikova, DV Shcheblyakov
The Lancet 397 (10288), 1883-1884, 2021
212021
Boosting of the SARS-CoV-2–specific immune response after vaccination with single-dose Sputnik light vaccine
AA Komissarov, IV Dolzhikova, GA Efimov, DY Logunov, O Mityaeva, ...
The Journal of Immunology 208 (5), 1139-1145, 2022
192022
Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
DA Burmistrova, SV Tillib, DV Shcheblyakov, IV Dolzhikova, ...
PLoS One 11 (3), e0150958, 2016
172016
Fast and accurate surrogate virus neutralization test based on antibody-mediated blocking of the interaction of ACE2 and SARS-CoV-2 spike protein RBD
DE Kolesov, MV Sinegubova, LK Dayanova, IV Dolzhikova, II Vorobiev, ...
Diagnostics 12 (2), 393, 2022
152022
A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV
AV Kovyrshina, IV Dolzhikova, DM Grousova, MV Balyasin, AG Botikov, ...
Immunology 41 (2), 135-143, 2020
142020
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
AI Tukhvatulin, IV Gordeychuk, IV Dolzhikova, AS Dzharullaeva, ...
Emerging Microbes & Infections 11 (1), 2229-2247, 2022
132022
系统目前无法执行此操作,请稍后再试。
文章 1–20